Sygnis Bioscience
Department of Molecular Neurology
Im Neuenheimer Feld 515
69120 Heidelberg

Germany

Homepage

Dr. Armin Schneider is Vice President of Molecular Neurology at Sygnis. He will be heading the proposed project at Sygnis. He directs a research program aimed at finding new treatments for neurodegenerative diseases and stroke, and currently also oversees clinical development of compounds. Dr. Schneider combines insights into molecular mechanisms of disease with an understanding of clinical issues. He received his degree from the University of Heidelberg, and had clinical training in the U.S. and in the neurology department in Heidelberg. He has authored more than 40 publications in the area of molecular neurobiology, among these publications in Nature, Nature Medicine, PNAS, Neuron, Science or JCI. His work is funded by grants from the BMBF, the NGFN, and the MJFF.
Dr. Claudia Pitzer is the Director of In vivo pharmacology at Sygnis, and will be responsible for animal experiments conducted in the project. Dr. Pitzer is biologist by training, and has received her degree from the University of Heidelberg. Dr. Pitzer heads the animal facility at Sygnis for several years.

Role in Project

Sygnis will study, in the context of the Neuroprotection team in ARISE, the interaction of the endogenous neuroprotectant G-CSF (Granulocyte-colony stimulating factor) and the lytic drug rt-PA (tissue plasminogen activator). We will employ biochemical, cell culture, and animal models. The outcome of these experiments has immediate impact on clinical trials of G-CSF in acute ischemic stroke.

Project Leader

Dr. Armin Schneider Vice President of Molecular Neurology Phone: +49 6221 454 713 Fax: +49 6221 454 700 Contact

Project Staff